Allogene Therapeutics ALLO Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$173.76M+9.0% | -$190.89M+10.0% | -$212.02M+10.5% | -$236.91M+6.1% | -$252.32M+2.0% | ||
| $12.13M-1.9% | $12.36M-1.4% | $12.54M-0.9% | $12.65M-4.1% | $13.18M-3.3% | ||
| $33.74M-10.4% | $37.64M-11.2% | $42.39M-10.0% | $47.12M-9.4% | $51.99M+0.5% | ||
| -$109.23M+26.8% | -$149.25M+5.7% | -$158.35M+8.4% | -$172.77M+12.4% | -$197.33M+1.5% | ||
| $296K-23.3% | $386K-40.0% | $643K-22.4% | $829K+5.6% | $785K+13.1% | ||
| $59.8M-37.4% | $95.56M-18.2% | $116.88M— | —— | —— | ||
| $37.29M+23.6% | $30.16M+7.5% | $28.04M+10.0% | $25.48M-80.2% | $129.02M+10.6% | ||
| —— | —— | —— | —— | —— | ||
| -$109.53M+26.8% | -$149.63M+5.9% | -$158.99M+8.4% | -$173.6M+12.4% | -$198.12M+1.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Allogene Therapeutics generate?
- Allogene Therapeutics (ALLO) generated -$109.2M in operating cash flow over the trailing twelve months.
- What is Allogene Therapeutics's free cash flow?
- After $296.0K of capital expenditures, Allogene Therapeutics's free cash flow was -$109.5M over the trailing twelve months, up 44.7% year over year.
- Where does Allogene Therapeutics's cash flow data come from?
- Every line is extracted from Allogene Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.